In vitro growth of Eμ-TCL1 leukemia cells with combined disruption of TP53, CDKN2A, CDKN2B, and MGA. (A) Schematic representation of the CRISPR/Cas9 procedure to target the TP53, CDKN2A, CDKN2B, and MGA genes in TCL1-863 leukemia cells. (B) Absolute number of viable TCL1-863 cells with TP53-targeted, TP53/CDKN2A/2B-targeted, TP53/CDKN2A/2B/MGA-targeted, or control TCL1-355 leukemia cells at different time points in culture. Each data point represents an average of 3 technical replicates. (C) Indel analysis by amplicon capillary electrophoresis of TP53/CDKN2A/2B/MGA-targeted leukemia cells at different time points in culture. The position of the wild-type allele is indicated by a red arrow.